

Supplement 1. Study drug titration scheme

Starting dose	
SBP ≥ 115 mmHg	Valsartan 160mg or matching placebo b.i.d.
SBP ≥ 105 but < 115 mmHg	Valsartan 80mg or matching placebo b.i.d.
Dose titration for participants taking valsartan 160 mg or matching placebo b.i.d.	
SBP ≥ 105 mmHg	Continue study treatment unchanged
SBP ≥ 95 but < 105	Lower study treatment to 80mg b.i.d.
SBP < 95 mmHg	Skip study treatment once
Dose titration for participants taking valsartan 80 mg or matching placebo b.i.d.	
SBP ≥ 95 mmHg	Continue study treatment unchanged
SBP < 95 mmHg	Skip study treatment once
For participants that skipped previous dosage due to SBP < 95mmHg	
SBP ≥ 95 mmHg	Start study treatment 80mg b.i.d.
SBP < 95 mmHg	Stop study treatment permanently
For the participant that meets the criteria for acute kidney injury	
Definition: 50% decline in estimated glomerular filtration rate relative to baseline, or decrease of > 30 ml/min/1.73m ² and to a value below 60 ml/min/1.73m ²	Stop study treatment permanently